FINANCIAL RESULTS

for the first half of

2026

23/07/2026

Laboratorios Farmacéuticos Rovi, S.A. ("ROVI",the "Company" or the "Group") and Subsidiaries - Investor Relations

KEY FIGURES

Summary

IN € MILLIONS	H1 2026	H1 2025	Growth	% Growth
Operating revenue(1)	344.2	314.6	29.6	9%
Gross profit(2)	237.1	196.2	40.9	21%
EBITDA(3)	121.2	65.6	55.6	85%
EBIT(4)	103.2	50.9	52.3	103%
Net profit(5)	84.4	39.7	44.7	113%
Purchases of property, plant and equipment and intangible assets ("Capex")	30.4	20.8	9.6	46%
FCF(6)	64.7	7.5	57.2	n.a.
Gross profit as % of operating revenue	68.9%	62.4%		6.5 pp
EBITDA as % of operating revenue	35.2%	20.9%		14.4 pp
EBIT as % of operating revenue	30.0%	16.2%		13.8 pp
Net profit as % of operating revenue	24.5%	12.6%		11.9 pp
Capex as % of operating revenue	8.8%	6.6%		2.2 pp
FCF as % of operating revenue	18.8%	2.4%		16.4 pp

IN € MILLIONS	As of June 30, 2026	As of Dec 31, 2025	Growth	% Growth
Net debt (-)/cash (+)(7)	22.5	(21.9)	44.4	n.a.

Note: certain numerical figures included in this document have been rounded. Therefore, discrepancies in tables between totals and the sums of the amounts listed may occur due to such rounding.

(1) Operating revenue refers to revenue.
(2) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.
(3) EBITDA calculated as profit before interest, taxes, depreciation and amortization.
(4) EBIT calculated as profit before taxes and interest.
(5) Net profit refers to profit for the period.
(6) Free Cash Flow (FCF) calculated as net cash generated from operating activities less purchases of property, plant and equipment and intangible assets ("Capex") plus proceeds from sale of property, plant and equipment plus interest received.
(7) Net debt (-)/cash (+) composed of equity securities, plus deposits, plus financial derivatives, plus cash and cash equivalents, less current and non-current financial debt.

The consolidated financial statements of Group ROVI for the first half of 2026 and the comparative information for 2025 (balance sheet) and for the first half of 2025 (consolidated income statement and cash flow statement) are attached to this report (see Appendix 1). There has been a limited review of the figures for the first half of 2025 and the first half of 2026 by the auditor. Likewise, the figures as of December 31, 2025 are audited figures.

CONTENTS

HIGHLIGHTS FIRST HALF 2026

ROVI REPORTED TOTAL REVENUE GROWTH OF 13.2% AND GROSS MARGIN EXPANSION OF 6.5 PERCENTAGE POINTS

- Total revenue amounted to 357.0 million euros in the first half of 2026, up 13.2% compared to 315.3 million euros in the same period of 2025.
- Operating revenue in the first half of 2026 was 344.2 million euros, up 9.4% compared to 314.6 million euros in the first half of 2025, mainly driven by the strong performance of the contract development and manufacturing business ("CDMO"), whose sales increased by 38% to 106.3 million euros in the first half of 2026.
- Okedi® (Risperidone ISM®) continued to post strong growth, reaching sales of 34.0 million euros in the first half of 2026, up 27% versus the first half of 2025.
- Sales of the heparin franchise (which includes low-molecular-weight heparins (LMWH) and other heparins) decreased by 4% to 130.1 million euros in the first half of 2026. This decrease was mainly attributable to the lower contribution from international bemiparin sales, as a result of high inventory levels held by partners.
- Gross profit increased by 21% in the first half of 2026 compared to the first half of 2025, reaching 237.1 million euros. Gross margin showed an increase of 6.5 percentage points year-on-year to 68.9% in the first half of 2026. This increase was impacted by the recognition of revenue associated with the R&D aid awarded by the CDTI for the LAISOLID project, which is recorded under the "Other income" line.
- On 1 April 2026, ROVI announced that the Asset Purchase Agreement signed between its subsidiary ROIS Phoenix Inc. and Bristol Myers Squibb for the acquisition of a pharmaceutical manufacturing plant located in Phoenix, Arizona (United States of America) together with a series of related assets and liabilities had been executed. The purchase price allocation (PPA) for the acquisition resulted in a bargain purchase gain, or "badwill," of 62.4 million euros. This was recognised as non-recurring income in the Group's consolidated income statement.
- EBITDA increased by 85% to 121.2 million euros in the first half of 2026, with an EBITDA margin of 35.2%, up 14.4 percentage points compared to the same period of 2025. Excluding the impact of the badwill, EBITDA decreased by 10% to 58.8 million euros, reflecting an EBITDA margin of 17.1%. Excluding both the impact of the badwill and R&D expenses, EBITDA increased by 12%, reflecting a 0.6 percentage point increase in the EBITDA margin.
- Net profit increased by 113% to 84.4 million euros in the first half of 2026.

- The ROVI General Shareholders Meeting, held on 17 June 2026, approved the payment of a gross dividend of 0.9594 euros per share; which represents approximately a 35% pay-out. This dividend was paid on 15 July 2026.

REVENUE BY REGION (%)



REVENUE BY BUSINESS UNIT (€Mn)



OUTLOOK

ROVI maintains its operating revenue outlook for 2026.

ROVI expects its **operating revenue to increase by a low- to mid-single-digit percentage compared to 2025**. This outlook is subject to various factors, the evolution of which remains difficult to predict accurately. Among the main factors taken into account when preparing this guidance, the following may be highlighted:

- Lower revenue forecast for 2026 under the prefilled syringe manufacturing agreement entered into with a global pharmaceutical company, which was disclosed as inside information on 25 April 2024. This is due, among other factors, to a delay in the initially expected commencement of routine manufacturing operations, which remains subject to the relevant regulatory authorisation, as well as increased uncertainty regarding anticipated demand, without prejudice to the minimum contractual obligations assumed by the two parties; and

- Growing competitive pressure on pricing in the heparin franchise in the current context of increased regulatory and geopolitical uncertainty and greater volatility in supply and cost dynamics. Additionally, the heparin franchise performed better than expected in 2025, mainly due to an increase in orders from international partners. Therefore, we expect lower orders from these partners in 2026 since they hold a high level of stocks.

In any event, the Company maintains a prudent approach to its outlook for 2026, reflecting the competitive environment and the current visibility of its main lines of business, which it will continue to monitor closely.

GAIN ON BARGAIN PURCHASE ARISING FROM THE ACQUISITION OF A MANUFACTURING FACILITY IN PHOENIX, ARIZONA

On 1 April 2026, ROVI announced the completion of the Asset Purchase Agreement signed between its subsidiary ROIS Phoenix Inc. ("ROIS Phoenix") and Bristol Myers Squibb ("BMS") for the acquisition of a pharmaceutical manufacturing facility in Phoenix, Arizona (United States), together with a number of related assets and liabilities. Completion of this purchase agreement took place after the customary closing conditions for transactions of this nature had been satisfied and in the absence of any significant adverse change since the agreement was signed.

Simultaneously, Rovi Pharma Industrial Services, S.A.U. and BMS entered into a Toll Manufacturing Agreement, with an initial term of five years, that sets out the conditions under which ROIS Phoenix will continue to manufacture for BMS at the facility.

As a result of the purchase price allocation process, a bargain purchase gain of 62.4 million euros was recognised and booked as non-recurring revenue in the consolidated income statement.

Likewise, when accounting for business combinations, there is a 12-month measurement period in which to evaluate the facts and circumstances existing at the acquisition date and, therefore, the measurement presented as of 30 June 2026 is considered provisional.

Juan López-Belmonte Encina, Chairman and Chief Executive Officer of ROVI, said: *"We see 2026 as a turning point at which we hope to return to a growth trajectory, supported by strategic decisions that we have been implementing over recent years. In this context, we have strengthened our position as a global industrial Group as a result of the acquisition of the injectable manufacturing facility in Phoenix (Arizona, U.S.A.) and by reinforcing our partnerships with leading pharmaceutical companies, such as Bristol Myers Squibb and Roche, expanding our international presence and our production capabilities. At the same time, we continue to promote our contract manufacturing division by expanding capacity and adding new services with a higher value-added, such as the assembly of advanced devices, including prefilled pens and autoinjectors. These investments place us in a privileged position to capture the opportunities arising from the growing imbalance between supply and demand in the market for highly-complex injectables. Innovation remains a cornerstone of our long-term growth strategy. The strong performance of Risperidone ISM® and the progress of our pipeline reinforce our confidence in the potential of ISM® technology. In this respect, projects to be highlighted include Letrozole SIE, a quarterly injectable formulation for the treatment of hormone-dependent breast cancer, and Risperidone QUAR®, a quarterly formulation to treat schizophrenia, both of which have the potential to improve treatment adherence and clinical efficacy. Likewise, we remain firmly committed to the low-molecular-weight heparin business, where we continue to progress with initiatives to enhance operational efficiency, reinforce vertical integration through the Glicopepton project, and restore the growth of one of the company's historical pillars. The combination of a robust industrial platform, a growing international presence and a clear commitment to innovation enables us to look to the future with confidence and places us in a favourable position to deliver sustainable growth and create long-term value for our shareholders and other stakeholders. "*

MANAGEMENT REPORT

for the six-month period ending June 30th, 2026

INCOME STATEMENT

IN € MILLIONS	H1 2026	H1 2025	Growth	% Growth
Operating revenue(1)	344.2	314.6	29.6	9%
Other income(2)	12.8	0.7	12.1	n.a.
Total revenue(3)	**357.0**	**315.3**	**41.7**	**13%**
Cost of goods sold(4)	(119.9)	(119.1)	(0.8)	1%
Gross profit(5)	**237.1**	**196.2**	**40.9**	**21%**
% margin(11)	*68.9%*	*62.4%*		*6.5 pp*
R&D expenses(6)	(33.3)	(16.8)	(16.5)	98%
SG&A(7)	(145.0)	(113.7)	(31.3)	28%
Gain on bargain purchase	62.4	—	62.4	n.a.
Share of profit in associates and joint ventures	0.1	(0.1)	0.2	n.a.
EBITDA(8)	**121.2**	**65.6**	**55.6**	**85%**
% margin(11)	*35.2%*	*20.9%*		*14.4 pp*
EBIT(9)	**103.2**	**50.9**	**52.3**	**103%**
% margin(11)	*30.0%*	*16.2%*		*13.8 pp*
Finance Income/(Costs)	(1.7)	(1.3)	(0.4)	32%
Profit before income tax	**101.6**	**49.6**	**51.9**	**105%**
Income tax	(17.2)	(9.9)	(7.3)	73%
Effective tax	*16.9%*	*20.0%*		*-3.1 pp*
Net profit(10)	**84.4**	**39.7**	**44.7**	**113%**
Net profit attributable to parent company	**84.5**	**39.7**	**44.7**	**113%**
Profit attributable to minority interests	**(0.1)**	**(0.04)**	**(0.06)**	**n.a.**

(1) Operating revenue refers to revenue.
(2) Other income includes the recognition of government grants on non-financial non-current assets and other.
(3) Total revenue calculated as revenue plus the recognition of government grants on non-financial non-current assets and other.
(4) Cost of sales calculated as the amount of procurements plus that corresponding to the change in inventories of finished goods and work in progress and raw materials and consumables use.
(5) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.
(6) R&D expenses are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.
(7) SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets" minus research & development expenses.
(8) EBITDA calculated as profit before interest, taxes, depreciation and amortization.
(9) EBIT calculated as profit before taxes and interest.
(10) Net profit refers to profit for the period.
(11)The gross margin and the EBITDA and EBIT margins are calculated as the result of dividing the gross profit, the EBITDA and the EBIT, respectively, by revenue, expressed as a percentage.

REVENUES

Total revenue by business unit

IN € MILLIONS	H1 2026	H1 2025	Growth	% Growth
Specialty pharmaceutical business	237.8	237.4	0.4	0.2%
CDMO business	106.3	77.2	29.1	38%
Other operating revenue(*)	0.1	—	0.1	n.a.
Operating revenue(1)	**344.2**	**314.6**	**29.6**	**9%**
Other income(2)	12.8	0.7	12.1	n.a.
Total revenue(3)	**357.0**	**315.3**	**41.7**	**13%**

(*) "Other operating revenue" includes service activities that are not material to the Group.
(1) Operating revenue refers to revenue excluding the recognition of government grants on non-financial non-current assets and other.
(2) Other income includes the recognition of government grants on non-financial non-current assets and other.
(3) Total revenue calculated as operating revenue plus the recognition of government grants on non-financial non-current assets and other.

Total revenue in the first half of 2026 amounted to 357.0 million euros, up 13% compared to 315.3 million euros in the same period of 2025. **Operating revenue** in the first half of 2026 was 344.2 million euros, up 9% compared to 314.6 million euros in the first half of 2025, mainly driven by the strong performance of the contract development and manufacturing business ("CDMO"), whose sales increased by 38% to 106.3 million euros in the first half of 2026.

Sales outside Spain increased 16% in the first half of 2026, compared to the first half of 2025, to 201.5 million euros, mainly driven by the strong performance of the CDMO business. Sales outside Spain represented 59% of operating revenue in the first half of 2026 compared to 55% in the first half of 2025.

SPECIALTY PHARMACEUTICAL BUSINESS

Sales of the specialty pharmaceutical business

IN € MILLIONS	H1 2026	H1 2025	Growth	% Growth
Prescription-based pharmaceutical products	**205.7**	**208.1**	**(2.4)**	**-1%**
LMWH franchise	125.3	131.3	(6.0)	-5%
Enoxaparin biosimilar	78.6	79.8	(1.3)	-2%
Bemiparin (Hibor)	46.7	51.5	(4.7)	-9%
Sales in Spain	27.6	28.5	(0.9)	-3%
International sales	19.1	23.0	(3.8)	-17%
Okedi	34.0	26.9	7.1	27%
Neparvis	28.2	27.7	0.6	2%
Volutsa	4.2	4.5	(0.3)	-7%
Orvatez	4.7	7.1	(2.4)	-33%
Other products	14.8	16.5	(1.7)	-10%
Discounts to the National Health System	(5.5)	(5.8)	0.3	-5%
Contrast agents and other hospital products	**31.6**	**28.7**	**2.8**	**10%**
Other products	**0.5**	**0.5**	**(0.1)**	**-11%**
Total specialty pharmaceutical business	**237.8**	**237.4**	**0.4**	**0.2%**

Sales of **prescription-based pharmaceutical** products decreased 1% to 205.7 million euros in the first half of 2026.

Sales of the **heparin franchise** (Low Molecular Weight Heparins and other heparins) decreased 4% to 130.1 million euros in the first half of 2026. Heparin sales represented 38% of operating revenue in the first half of 2026 compared to 43% in the first half of 2025.

Heparin franchise

IN € MILLIONS	**H1 2026**	H1 2025	Growth	% Growth
LMWH franchise	125.3	131.3	(6.0)	-5%
Enoxaparin biosimilar	78.6	79.8	(1.3)	-2%
Bemiparin (Hibor)	46.7	51.5	(4.7)	-9%
Sales in Spain	27.6	28.5	(0.9)	-3%
International sales	19.1	23.0	(3.8)	-17%
Other heparins[1]	4.8	4.0	0.9	23%
Heparins franchise	**130.1**	**135.2**	**(5.1)**	**-4%**

LOW MOLECULAR WEIGHT HEPARINS

Sales of **Low Molecular Weight Heparins (LMWH)** (enoxaparin biosimilar and bemiparin) decreased 5% to 125.3 million euros in the first half of 2026. This decrease was mainly attributable to the weaker performance of bemiparin, particularly in international sales, as a result of high inventory levels held by partners.

As a result of a better-than-expected performance, ROVI expects low-molecular-weight heparin (LMWH) sales to decrease by a mid-single-digit percentage in 2026, compared with the previous guidance of a high-single-digit decrease. Nevertheless, their performance will continue to be affected primarily by: (i) lower order volumes expected from partners in 2026, since they hold high levels of stocks from the previous year, and (ii) growing competitive pressure on prices.

IN € MILLIONS	**Q2 2024**	Q3 2024	Q4 2024	Q1 2025	**Q2 2025**	Q3 2025	Q4 2025	Q1 2026	**Q2 2026**
Enoxaparin biosimilar	35.1	31.8	43.6	40.6	39.2	33.0	44.9	41.2	37.4
Bemiparin (Hibor)	27.5	23.9	25.3	27.1	24.3	19.3	29.6	17.7	29.0
Sales in Spain	15.1	13.5	14.6	14.4	14.1	13.5	14.7	14.3	13.3
Intl. sales	12.4	10.4	10.7	12.7	10.2	5.8	14.8	3.5	15.7
Total LMWH sales	**62.6**	**55.7**	**69.0**	**67.7**	**63.6**	**52.3**	**74.5**	**58.9**	**66.4**

Sales of the **enoxaparin biosimilar** decreased by 2% year-on-year to 78.6 million euros in the first half of 2026.

Bemiparin sales decreased by 9% to 46.7 million euros in the first half of 2026 compared with the first half of 2025. This performance was mainly driven by a contraction in international sales, which fell by 17% to 19.1 million euros, largely reflecting overstocking by international partners in the first half of 2026. Sales in Spain (Hibor®) decreased by 3% to 27.6 million euros, primarily due to lower penetration in the prophylaxis segment.

[1] *Other heparins are reported in the "Contrast agents and other hospital products" line.*

Despite the year-on-year decline during the first half of 2026, bemiparin international sales showed a strong recovery in the second quarter of 2026, increasing by 53% versus the second quarter of 2025 and by more than threefold compared with the first quarter of 2026. For 2026, ROVI expects bemiparin sales to increase in the low single-digit percentage compared with 2025.

OTHER PRESCRIPTION-BASED PHARMACEUTICAL PRODUCTS

Sales of **Okedi®**, the first ROVI product based on its leading-edge drug delivery technology, ISM®, and indicated for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone, reached 34.0 million euros in the first half of 2026, up 27% versus the first half of 2025. During the first half of 2026, the product was marketed in Germany, UK, Spain, Portugal, Italy, Austria, Greece, Serbia, the Nordic countries, Australia, Taiwan and the Netherlands.

Sales of **Neparvis®**, a specialty product from Novartis, launched in Spain in December 2016, indicated for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction, increased 2% to 28.2 million euros in the first half of 2026, compared to 27.7 million euros in the first half of 2025. The current Neparvis® distribution agreement expires on October 16, 2026.

Sales of **Volutsa®**, a specialty product from Astellas Pharma indicated for the treatment of moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia, launched in Spain in February 2015, decreased by 7% to 4.2 million euros in the first half of 2026, mainly due to the competitive environment following the entry of generics in the second quarter of 2023.

Sales of **Orvatez®**, a specialty product from Organon & Co. ("Organon") indicated as adjunctive therapy to diet in patients with hypercholesterolemia, decreased by 33% to 4.7 million euros in the first half of 2026, compared to the first half of 2025. This decrease was mostly caused by the entry of generics into the market, which resulted in a product price reduction by competitors. ROVI consequently dropped the price of Orvatez® by 40% in October 2024.

CONTRAST AGENTS AND OTHER HOSPITAL PRODUCTS

Sales of **contrast imaging agents and other hospital products** increased by 10% to 31.6 million euros in the first half of 2026.

CDMO BUSINESS

CDMO sales increased 38% to 106.3 million euros in the first half of 2026 in comparison with the first half of 2025, mainly driven by: (i) the growth in business with existing customers following the restoration of full operational capacity at the Madrid facility after its temporary closure during the first half of 2025 to upgrade some Annex 1 GMP aspects for aseptic manufacturing; and (ii) the contribution of revenue generated under the supply agreement with Bristol Myers Squibb entered into in connection with the acquisition of the Phoenix facility, completed on April 1, 2026. Revenue from this customer accounted for approximately 13% of total CDMO revenue in the first half of 2026.

Over the past years, ROVI has invested substantial capital to build global leadership in sterile fill & finish (F&F) capacity and technology services. With these recent investments, and with current expansions underway, ROVI expects to significantly increase its current sterile capacity at its FDA (Food and Drug Administration) and EMA (European Medicine Agency) / EU GMP Annex-1 compliant facilities in Spain. This will allow ROVI to continue to capitalize on the imbalance between the available capacity and the rising demand across the sterile fill & finish market, building on the good drive in commercial activity and alliance opportunities across strategic high-growth modalities – including innovative biologics, biosimilars, vaccines and novel modalities for pre-filled syringes and cartridges.

OTHER INCOME

Other income (grants) increased by 12.1 million euros to 12.8 million euros in the first half of 2026 compared with the first half of 2025. This increase mainly reflects the recognition of revenue related to the €36.3 million R&D aid awarded by the Technological Development and Innovation Centre (CDTI) for the LAISOLID project. Following the final decision published on 9 July 2025 confirming the grant covering the period from January 2023 to August 2026, the full amount of which was received upon approval. In the first half of 2026, the Company recognized as revenue only the expenses incurred during this period.

COSTS

GROSS PROFIT

Gross profit increased 21% to 237.1 million euros in the first half of 2026. Gross margin showed an increase of 6.5 percentage points, from 62.4% in the first half of 2025 to 68.9% in the first half of 2026. This increase was impacted by the recognition of revenue associated with the R&D aid awarded by the CDTI for the LAISOLID project, which is recorded under the "Other income" line. Excluding the impact of "Other income", gross margin would have increased by 3.0 percentage points to 65.2% mainly due to: (i) the increase in the CDMO business which contributed higher margins to Group sales, (ii) the increased contribution of Okedi® sales, which added high margins, and (iii) the decrease in LMWH raw material prices, which had a positive impact on gross margin.

RESEARCH AND DEVELOPMENT EXPENSES

R&D expenses increased by 98% to 33.3 million euros in the first half of 2026. They were mainly related to the preparation for the development of the phase III clinical trial of Letrozole SIE.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

SG&A expenses increased 27% to 145.0 million euros in the first half of 2026 compared with the first half of 2025. This decrease was mainly due to:

- higher "Employee benefit expenses (excl. R&D)," which increased 23% year-on-year, driven primarily by (i) the addition of ROIS Phoenix Inc.'s employees following the company's inclusion in the Group's consolidation perimeter, (ii) a 3% wage increase due to the entry into force of the XXI Collective Agreement of the

Chemical Industry 2024-2026[2], (iii) the hiring of new CDMO personnel, and (iv) the recognition of non-recurring expenses resulting mainly from the tax audit and investigation procedures carried out by the Tax and Customs Control Office of the Large Taxpayers Central Office regarding withholding taxes and advance tax payments on employment income, professional income and economic activities for the period between September 2020 and December 2022. Excluding non-recurring expenses, "Employee benefit expenses (excl. R&D)," increased by 20% in the first half of 2026; and

- higher "Other operating expenses (excl. R&D)," which increased 34% year-on year. This increase was mainly driven by (i) the incorporation of ROIS Phoenix Inc. into the Group's consolidation perimeter, (ii) lower operating expenses in the first half of 2025, a period during which they were reduced as a result of the temporary closure of the Madrid facility to upgrade some Annex 1 GMP aspects for aseptic manufacturing, and (iii) the recognition of non-recurring expenses mainly associated with the write-off of assets that are no longer operational and the execution of certain strategic projects. Excluding non-recurring expenses, "Other operating expenses (excl. R&D)" increased by 28% in the period.

Expenses related to ROIS Phoenix Inc. represented approximately 9% of SG&A expenses in the first half of 2026.

"SG&A expenses (excl. R&D and non-recurring expenses)" increased by 24% to 140.5 million euros in the first half of 2026 compared to the first half of 2025.

For 2026, ROVI expects SG&A expenses (excluding ROIS Phoenix Inc. from the Group) to increase by a mid- to high-single-digit percentage compared with 2025.

SG&A expenses

IN € MILLIONS	H1 2026	H1 2025	Growth	% Growth
Employee benefit expenses (excl. R&D)	79.4	64.6	14.8	23%
of which non-recurring expenses	1.6	—	(1.6)	n.a.
Other operating expenses (excl. R&D)	65.6	49.1	16.5	34%
of which non-recurring expenses	2.9	0.1	2.9	n.a.
Total SG&A expenses	**145.0**	**113.7**	**31.3**	**28%**

DEPRECIATION

Depreciation and amortisation expenses increased by 22% to 18.0 million euros in the first half of 2026, as a result of the new property, plant and equipment and intangible asset purchases made during the last year.

NET FINANCIAL INCOME

Net financial costs reached 1.7 million euros in the first half of 2026, compared to net financial costs of 1.3 million euros in the first half of 2025. This increase was mainly driven by higher finance costs as a result of late-payment interest associated with the tax audit

2 Source: https://www.feique.org/wp-content/uploads/2024/11/XXI-CONVENIO-GENERAL-DE-LA-INDUSTRIA-QUIMICA.pdf covering fiscal years 2020 to 2022. This impact was partially offset by (i) gains arising from changes in the fair value of financial instruments, and (ii) positive exchange differences. Excluding the financial costs associated with the tax audit, net financial result would have amounted to an expense of €0.3 million in the first half of 2026, reflecting a 79% improvement compared with the net financial expense recorded in the first half of 2025.

EFFECTIVE TAX RATE

The **effective tax rate** decreased by 3.1 percentage points from 20.0% in the first half of 2025 to 16.9% in the first half of 2026. This reduction was mainly attributable to the recognition of a gain on a bargain purchase (badwill) arising from the acquisition of the Phoenix facility, which was recorded as accounting income with no tax impact, thereby reducing the effective tax rate for the period.

TAX AUDIT

On 13 November 2024, Laboratorios Farmacéuticos Rovi, S.A. and Rovi Pharma Industrial Services, S.A. were notified of the commencement of audit and investigation procedures by the Large Taxpayers Central Office, Office of Tax and Customs Control in relation to the following items and periods:

- Corporate income tax for the years 2020 to 2022.
- Value-added tax from September 2020 to December 2022.
- Withholdings/payments on account of earned income and income from professional and business activities from September 2020 to December 2022.
- Withholdings on account of non-residents' income tax from September 2020 to December 2022.

As at 30 June 2026, the procedures for the years 2020-2022 had been concluded by the tax authorities and the relevant assessments were formally signed on 6 July 2026.

No penalty proceedings arose from the procedures carried out by the audit team. The principal impacts on the Group's financial statements are set out below:

MILLION €	P&L impact	Balance sheet impact	
		Non-current assets	Current liabilities
Selling, general and administrative expenses(1)	0.9		
Finance costs	0.8		
Income tax	0.1		
Deferred tax assets		5.1	
Trade and other payables			7.0
Total	**1.9**	**5.1**	**7.0**

(1) *SG&A calculated as the amount of* employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets" minus research & development expenses.

The deferred tax asset recognised relates to the tax treatment of certain income and expenses related to the investments made to adapt the Group's facilities for commercial manufacturing. As a result of a difference in criteria between the ROVI Group and the tax authorities regarding the tax accounting for certain assets acquired within the framework of these investments, an agreed settlement ("*acta con acuerdo*") was signed, amending the tax bases for corporate income tax for the years 2020, 2021 and 2022. This amendment led to recognition of a deferred tax asset of 5.1 million euros, which is expected to be recovered in future years.

Likewise, ROVI assessed the potential tax risks for the years 2023-2024 and, as a result of this assessment, recognised an expense of 1.1 million euros in profit or loss and a deferred tax asset of 8.1 million euros.

Additionally, the Group revised the corporate income tax provision for 2025 resulting in recognition of a deferred tax asset for 1.0 million euros and a current tax liability for the same amount.

FINANCIAL PERFORMANCE

Million euros



(1)Net profit refers to the profit for the period.
(2)Gross profit calculated as total revenue less change in inventories of finished goods and work in progress and raw materials and consumables used.
(3)*SG&A calculated as the amount of* employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets"minus research & development expenses.
(4)*R&D expenses* are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.

EBITDA

EBITDA increased by 85% to 121.2 million euros in the first half of 2026, with an EBITDA margin of 35.2%, up 14.4 percentage points compared to the same period of 2025. This performance mainly reflects the impact of the gain on bargain purchase.

EBITDA excluding badwill decreased by 10% to 58.8 million euros in the first half of 2026, with EBITDA margin standing at 17.1%.

EBIT

EBIT increased by 103% compared to the first half of 2025, reaching 103.2 million euros in the first half of 2026. This performance resulted in a 13.8 percentage point improvement in EBIT margin, which stood at 30.0% in the first half of 2026, up from 16.2% in the first half of 2025.

EBIT excluding badwill decreased by 20% to 40.9 million euros in the first half of 2026, with EBIT margin standing at 11.9%.

NET PROFIT

Net profit amounted to 84.4 million euros in the first half of 2026, compared to 39.7 million euros in the same period of 2025, representing an increase of 113%.

Non-controlling interests refer to ROVI's partners in Glicopepton Biotech, S. L. and Cells IA Technologies, S.L.

PRE-R&D/FLAT R&D AND PRE-BADWILL

EBITDA "Pre-R&D and Pre-Badwill", calculated excluding badwill in the first half of 2026 and R&D expenses in the first half of 2026 and the first half of 2025, increased by 12%, from 82.4 million euros in the first half of 2025 to 92.2 million euros in the same period of 2026, reflecting a 0.6 percentage point increase in the EBITDA margin to 26.8% in the first half of 2026 (see "Pre-R&D costs and Pre-Badwill" columns of the table below). Likewise, recognizing the same amount of R&D expenses in the first half of 2026 as in the same period of 2025, EBITDA would have increased by 15% to 75.4 million euros, reflecting a 1.0 percentage point increase in the EBITDA margin to 21.9% in the first half of 2026, up from 20.9% in the same period of 2025 (see "Flat R&D costs and Pre-Badwill" columns of the table below).

EBIT "Pre-R&D and Pre-Badwill", calculated excluding badwill in the first half of 2026 and R&D expenses in the first half of 2026 and the first half of 2025, increased by 10%, from 67.7 million euros in the first half of 2025 to 74.2 million euros in the same period of 2026, reflecting a flat EBIT margin of 21.6% compared with the first half of 2025 (see "Pre-R&D costs and Pre-Badwill" columns of the table below). Likewise, recognizing the same amount of R&D expenses in the first half of 2026 as in the first half of 2025, EBIT would have increased by 13% to 57.4 million euros, reflecting a 0.5 percentage point increase in the EBIT margin to 16.7% in the first half of 2026, up from 16.2% in the first half of 2025 (see "Flat R&D costs and Pre-Badwill" columns of the table below).

Pre-R&D/Flat R&D and Pre-Badwill

IN € MILLIONS	Reported		Pre-R&D costs and Pre-Badwill			Flat R&D costs and Pre-Badwill		
	H1 2026	H1 2025	**H1 2026**	H1 2025	% Cto.	**H1 2026**	H1 2025	% Cto.
Operating revenue(1)	344.2	314.6	344.2	314.6	9%	344.2	314.6	9%
Other income(2)	12.8	0.7	12.8	0.7	n.a.	12.8	0.7	n.a.
Total revenue(3)	**357.0**	**315.3**	**357.0**	**315.3**	**13%**	**357.0**	**315.3**	**13%**
Cost of sales(4)	(119.9)	(119.1)	(119.9)	(119.1)	1%	(119.9)	(119.1)	1%
Gross profit(5)	**237.1**	**196.2**	**237.1**	**196.2**	**21%**	**237.1**	**196.2**	**21%**
% margin(11)	*68.9%*	*62.4%*	*68.9%*	*62.4%*	*6.5 pp*	*68.9%*	*62.4%*	*6.5 pp*
R&D expenses(6)	(33.3)	(16.8)	0.0	0.0	n.a.	(16.8)	(16.8)	n.a.
SG&A(7)	(145.0)	(113.7)	(145.0)	(113.7)	28%	(145.0)	(113.7)	28%
Gain on bargain purchase	62.4	0.0	0.0	0.0	n.a.	0.0	0.0	n.a.
Share of profit in associates and joint ventures	0.1	(0.1)	0.1	(0.1)	n.a.	0.1	(0.1)	n.a.
EBITDA(8)	**121.2**	**65.6**	**92.2**	**82.4**	**12%**	**75.4**	**65.6**	**15%**
% margin(11)	*35.2%*	*20.9%*	*26.8%*	*26.2%*	*0.6 pp*	*21.9%*	*20.9%*	*1.0 pp*
EBIT(9)	**103.2**	**50.9**	**74.2**	**67.7**	**10%**	**57.4**	**50.9**	**13%**
% margin(11)	*30.0%*	*16.2%*	*21.6%*	*21.5%*	*0.0 pp*	*16.7%*	*16.2%*	*0.5 pp*

(1) Operating revenue refers to revenue.
(2) Other income includes the recognition of government grants on non-financial non-current assets and other.
(3) Total revenue calculated as revenue plus the recognition of government grants on non-financial non-current assets and other.
(4) Cost of sales calculated as the amount of procurements plus that corresponding to the change in inventories of finished goods and work in progress and raw materials and consumables use.
(5) Gross profit calculated as revenue plus the recognition of government grants on non-financial non-current assets and other less change in inventories of finished goods and work in progress and raw materials and consumables used.
(6) *R&D expenses* are calculated as the sum of employee benefit expenses and other operating expenses related to scientific research and technological development.
(7) *SG&A calculated as the amount of* employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets minus research & development expenses.
(8) EBITDA calculated as profit before *interest, taxes, depreciation and amortization.*
(9) EBIT calculated as profit before taxes and interest.
(10) Net profit refers to profit for the period.
(11) The gross margin and the EBITDA, EBIT and net profit margins are calculated as the result of dividing the gross profit, the EBITDA, the EBIT and the net profit, respectively, by revenue, expressed as a percentage.

DIVIDEND

ROVI's General Shareholders Meeting, held on 17 June 2026, approved the payment of a dividend equivalent to 0.9594 euros per share entitled to receive it, charged to the 2025 profit. This would entail distribution to an amount equivalent to approximately 35% of the consolidated net profit for 2025 attributed to the parent company. This dividend was paid on 15 July 2026.

FINANCIAL POSITION

Balance Sheet

IN € MILLIONS	June 30, 2026	December 31, 2025	Growth	% Growth
Assets				
Non-current assets	559.1	389.0	170.1	44%
Current assets	568.0	566.7	1.2	0%
Total assets	**1,127.0**	**955.7**	**171.3**	**18%**
Equity	**717.1**	**675.5**	**41.6**	**6%**
Liabilities				
Non-current liabilities	133.4	99.0	34.4	35%
Financial debt	80.5	93.2	(12.7)	-14%
Current liabilities	276.5	181.2	95.3	53%
Financial debt	27.1	28.6	(1.5)	-5%
Total liabilities	**410.0**	**280.2**	**129.7**	**46%**
Total equity and liabilities	**1,127.0**	**955.7**	**171.3**	**18%**

TOTAL ASSETS

ROVI's **total assets** increased 18%, from 955.7 million euros as of December 31, 2025 to 1,127.0 million euros as of June 30, 2026, mainly because of (i) an increase of 154.9 million euros in "Property, Plant and equipment" as a result of the incorporation of ROIS Phoenix Inc. in the Group's consolidation perimeter, (ii) an increase of 15.3 million euros in "Deferred income tax assets", mainly related to the agreement reached between the ROVI Group and the Spanish Tax Agency regarding the amendment of the taxable bases for fiscal years 2020, 2021 and 2022 in the context of the corporate income tax audit, and (iii) an increase of 29.0 million euros in "Cash and cash equivalents."

EQUITY

ROVI's **equity** increased by 6% to 717.1 million euros as of June 30, 2026, mainly as a result of the increase in profit for the period.

TOTAL LIABILITIES

ROVI's total **liabilities** increased by 46% from 280.2 million euros as of 31 December, 2025 to 410.0 million euros as of 30 June, 2026. This increase was mainly due to (i) an increase of 67.4 million euros in "Trade and other payables", primarily attributable to the recognition of the dividend payable as of 30 June 2026; (ii) an increase of 46.4 million euros in "Contract liabilities", and (iii) an increase of 21.6 million euros in "Deferred income tax liabilities", all resulting from the incorporation of ROIS Phoenix Inc. in the Group's consolidation perimeter.

As of 30 June, 2026, ROVI **total debt** decreased to 107.7 million euros.

Total Debt

IN € THOUSANDS	June 30, 2026	December 31, 2025	Interest rate
Bank borrowings	84,893	94,994	0.68-3.00
Debt with public administration	10,059	11,043	—
Financial liabilities for leases	12,738	15,687	—
Derivative financial instruments	—	97	—
Total	**107,690**	**121,821**	

As of 30 June, 2026, bank borrowings decreased by 10.1 million euros.

Bank borrowings are composed of:

Instrument	Opening balance (€m)	Outstanding balance (€m)	Maturity	Interest rate	Current rate
Loan BEI 2017	45.0	21.6			
(i) Variable tranche	5.0	1.6	2028	Euribor 3M + 0.844%	3.014%
(ii) Fixed tranche	40.0	20.0	2029	0.681%	0.681%
Loan BEI 2022*	10.0	10.0	2032	Euribor 3M + 0.655%	2.849%
Bank loan 2024	25.0	15.4	2029	3.0% fixed	3.000%
Bank loan 2025	46.5	37.7	2030	2.75% fixed	2.750%

Note: Bank borrowings are amortised on a quarterly basis.
**Although the amount granted was 50 million euros, only 10 million euros has been drawn. No further funds will be drawn under this facility, as the period available for new drawdowns ended in July 2024.*

Additionally, ROVI holds three credit facilities for 20 million euros each. No drawdowns had been made against any of them as of 30 June 2026.

Instrument	Opening balance (€m)	Outstanding balance (€m)	Maturity	Interest rate
Credit facility	20.0	Not drawn	2026	Euribor 3M + 0.50%
	20.0	Not drawn	2027	
	20.0	Not drawn	2027	

GROSS CASH POSITION AND NET DEBT (-)/CASH (+)

As of 30 June, 2026, ROVI had a **gross cash position** of 130.2 million euros, compared to 99.9 million euros as of 31 December, 2025, and **net cash** of 22.5 million euros, compared to net debt of 21.9 million euros as of 31 December, 2025.

Gross cash position and net debt (-)/cash (+)

IN € MILLIONS	June 30, 2026	December 31, 2025
Deposits	2.2	1.9
Financial assets at amortised cost	1.1	—
Cash and cash equivalents	127.0	98.0
Gross cash position	**130.2**	**99.9**
Financial debt	(107.7)	(121.8)
Net debt/cash	**22.5**	**(21.9)**

Net cash generated in operating activities amounted to 94.3 million euros in the first half of 2026, compared to 28.0 million euros in the first half of 2025.

Million euros



(1) Net debt (-) /cash (+) is composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt.

LIQUIDITY

Cash Flow

IN € MILLIONS	H1 2026	H1 2025	Growth	% Growth
Cash flow from operating activities	94.3	28.0	66.2	n.a.
Cash flow from investing activities	(53.7)	(21.9)	(31.8)	n.a.
Cash flow from financing activities	(11.7)	12.8	(24.5)	n.a.
Exchange rate differences	0.1	—	0.1	n.a.
Net increase/ (decrease) in cash	**29.0**	**18.9**	**10.1**	**53%**
Cash at the beginning of the year	98.0	27.2	70.8	n.a.
Cash at the end of the period	**127.0**	**46.1**	**80.9**	**n.a.**

Note: the amount reported in the first half 2025 as "Cash due to change in consolidation perimeter" has been reclassified and is presented in the first half 2026 press release under "Cash flow from investing activities."

CASH FLOW FROM OPERATING ACTIVITIES

Cash flow from operating activities increased to 94.3 million euros in the first half of 2026 from 28.0 million euros in the same period of 2025. This increase was mainly due to:

- the increase of 9.3 million euros in "Trade and other payables" item in the first half of 2026, compared to a decrease of 25.6 million euros in the first half of 2025;
- the increase of 16.4 million euros in "Inventories" item in the first half of 2026, compared to an increase of 6.3 million euros in the same period of 2025;
- the increase of 15.1 million euros in "Trade and other receivables" item in the first half of 2026, compared to an increase of 8.6 million euros in the same period of 2025; and
- the increase of 10.1 million euros in "Cash flow from contract manufacturing services" item in the first half of 2026, compared to a decrease of 17.2 million euros in the first half of 2025.

CASH FLOW FROM INVESTING ACTIVITIES

ROVI invested 30.4 million euros in the first half of 2026, compared to 20.8 million euros in the first half of 2025.

Purchases of property, plant and equipment and intangible assets ("Capex")

IN € MILLIONS	H1 2026	H1 2025	Growth	% Growth
Madrid Injectable plant	2.1	0.6	1.5	n.a.
San Sebastián de los Reyes plant	3.1	1.2	1.9	n.a.
Granada plant	0.1	0.2	(0.1)	-43%
Alcalá de Henares plant	1.5	1.2	0.4	33%
Escúzar plant	0.1	1.2	(1.1)	-89%
Phoenix plant	0.2	0.0	0.2	n.a.
Expenditure on maintenance and other capex	1.4	0.9	0.5	58%
Maintenance Capex	**8.5**	**5.2**	**3.4**	**66%**
ISM industrialisation	1.3	0.4	0.9	n.a.
Glicopepton	9.1	3.7	5.4	n.a.
New filling lines and operations expansion	11.5	11.6	(0.1)	-1%
Investment Capex	**21.9**	**15.7**	**6.2**	**40%**
Total Capex	**30.4**	**20.8**	**9.6**	**46%**

FREE CASH FLOW

Free cash flow increased to 64.7 million euros in the first half of 2026 from 7.5 million euros in the same period of 2025.

Free cash flow

IN € MILLIONS	H1 2026	H1 2025
Net cash generated from (used in) operating activities	94.3	28.0
Acquisitions of intangible assets	(1.5)	(0.7)
Acquisitions of property, plant and equipment	(28.9)	(20.2)
Proceeds from sale of property, plant and equipment	—	0.1
Interest received	0.9	0.2
Free cash flow	**64.7**	**7.5**

CASH FLOW FROM FINANCING ACTIVITIES

Cash flow from financing activities was (11.7) million euros in the first half of 2026 versus 12.8 million euros in the same period of 2025. This variation was mainly caused by (i) the absence of new financing received in the first half of 2026, compared with 46.5

million euros raised in the first half of 2025, and (ii) the increase in treasury share purchases, which totalled 39.3 million euros, compared with 28.4 million euros in the same period of the previous year. These impacts were partially offset by (i) lower cash outflows related to the repayment of financial debt, which amounted to 14.5 million euros in comparison with 32.6 million euros in the first half of 2025, and (ii) higher proceeds from the reissuance of treasury shares to third parties, which increased to 38.8 million euros in the first half of 2026 from 28.4 million euros in the first half of 2025.

Javier López-Belmote Encina, Deputy Chairman and Chief Financial Officer of ROVI, said: *As 2026 progresses, we are returning to a path of sustainable growth. In this context, in the first half of 2026, operating revenue rose 9% to 344.2 million euros. Likewise, gross profit grew by 21% and gross margin improved by 6.5 percentage points to 68.9%. This increase was driven by the growth of the CDMO business, a higher contribution from Risperidone ISM®, a decrease in LMWH raw material prices, and recognition of the revenue associated with the R&D grant awarded by the CDTI for the LAISOLID project. In parallel, reported EBITDA increased 85% to 121.2 million euros. This increase is explained by the effect of the bargain purchase gain (badwill) arising from the acquisition of the manufacturing facility in Phoenix, Arizona (U.S.A.). Excluding this effect, EBITDA stood at 58.8 million euros. At the same time, we have continued to strengthen our commitment to innovation, allocating 33.3 million euros to R&D activity in the first half of 2026. Excluding both badwill and R&D expenses, EBITDA increased by 12%. Likewise, we also remain firmly committed to creating value for our shareholders. In this respect, on 15 July 2026, we paid a dividend of 0.9594 euros per share, charged against the 2025 profit and unrestricted reserves. For 2026, in the light of the current performance of certain business variables and the information available, we expect operating revenue to increase by a low- to mid-single-digit percentage compared with 2025. This forecast reflects a prudent approach, consistent with a demanding competitive environment and the current level of visibility of our principal lines of business, whose performance we will continue to monitor closely."*

R&D UPDATE

ISM® technology platform

ROVI is developing Letrozole SIE (Superior Inhibition of Estrogens) (formerly Letrozole LEBE) for the treatment of hormone receptor-positive breast cancer. This investigational medicine is expected to be superior to the oral letrozole (Femara®[3]) marketed currently due to its increased oestrogen suppression which is expected to result in clinical benefits.

Accordingly, its clinical development plan includes an efficacy trial in postmenopausal women with advanced breast cancer designed to demonstrate the superior efficacy of Letrozole SIE versus Femara® in delaying disease progression (SIE-3[4]).

This new investigational medicine is planned to follow the regulatory pathway 505(b)(2) in the United States and a hybrid application (under Article 10(3) of Directive 2001/83/EC) will be filed in Europe, seeking marketing authorisation with the same therapeutic indications as Femara® in both the United States and Europe. This would allow Letrozole SIE to be used at all the stages of breast cancer in postmenopausal women with oestrogen receptor-positive tumours.

A single-dose phase I study (LEILA-1)[5] conducted in Europe has recently finished (currently under final data analysis). The preliminary results support the progression to the next steps of the clinical develop programme.

Consequently, the Investigational New Drug (IND) Application of Letrozole SIE has already been approved by the US Food and Drug Administration (FDA). Recruitment for the following clinical trials, including a phase III efficacy clinical trial, is expected to start in the third quarter of 2026.

Furthermore, ROVI is also developing Risperidone QUAR, a quarterly long-acting risperidone injection. The first phase I clinical trial with ascending doses[6] has already finished and final data confirm that this formulation, similarly to Okedi®, is able to provide plasma levels in the therapeutic range on the same day as the injection without the need for prior injections of monthly formulations, loading doses or concomitant oral risperidone doses, and to maintain them, on a sustained basis, with little accumulation, in the following doses, making the clinical efficacy very predictable and improving tolerability. Consequently, ROVI is currently starting up two new multinational clinical studies, including a phase III efficacy trial. Patient enrolment is planned to begin by the fourth quarter of 2026.

Most patients suffering from schizophrenia have a lack of insight into their disease, resulting in lack of adherence. Risperidone QUAR will allow patients who are admitted to hospital because their condition is deteriorating to be treated with a single injection covering the three most important months, from the early moments of the episode to the stabilisation of the patient.

3 Femara® is a registered trademark of Novartis AG

4 A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3). National Library of Medicine. Clinicaltrials.gov. NCT07340658 (available at: https://clinicaltrials.gov/study/NCT07340658).

5 Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women (LEILA-1). National Library of Medicine. Clinicaltrials.gov. NCT06315205 (available from: https://clinicaltrials.gov/study/NCT06315205

6 Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (QUARTZ). National Library of Medicine. Clinicaltrials.gov. NCT06276361 (available from: https://clinicaltrials.gov/study/NCT06276361).

ROVI plans to register this new medicine in the European Union through a hybrid application (under Article 10(3) of Directive 2001/83/EC), for which it has designed a clinical programme similar to the one previously executed for Okedi®, with the objective of obtaining the same therapeutic indication as the latter: treatment of schizophrenia in adults for whom tolerability and effectiveness have been established with oral risperidone.

ESG

ROVI was included on the IBEX ESG index, managed by Bolsas y Mercados Españoles (BME), of which 48 companies belonging to either the IBEX 35 or IBEX Medium Cap form part. This index recognises the listed companies with the best environmental, social and governance (ESG) performances. Inclusion on the IBEX ESG reinforces ROVI's commitment to decarbonisation and the creation of sustainable value for all its stakeholders.

In December 2025, ROVI's Board of Directors approved a new five-year Master Plan (2026-2030), structured around three core concepts through KPIs which, if they are fulfilled, will guide the transformation towards a more responsible and sustainable business model.

The Group's priority focus is on the following three strategic pillars:

- Environmental protection: focused on climate change mitigation, promoting the circular economy, and efficient and responsible resources management.
- Social management: ROVI devotes its efforts to managing talent and reinforcing the corporate culture as well as promoting employee well-being, ensuring safety in the operations and creating a positive social impact.
- Responsible governance: the company emphasises its culture of integrity, extends its standards of ethics and environmental protection to its value chain and integrates sustainability into the decision-making of the chief governance bodies.

Additionally, ROVI, as a member of the United Nations Global Compact supports, by adopting and disseminating them, the integration of the principles of said Compact and other international instruments, especially in the areas of human rights, workplace practices, the environment and the fight against corruption.

About the LAISOLID Project

Laboratorios Farmacéuticos ROVI is developing LAISOLID, a strategic research and development project funded by the Centre for the Development of Technology and Innovation (CDTI) under the Recovery, Transformation and Resilience Plan, financed by the European Union through NextGenerationEU.

LAISOLID is an R&D initiative aimed at developing aseptic filling technologies for complex polymeric matrices capable of containing cells and biological materials for regenerative medicine therapies, as well as incorporating active pharmaceutical ingredients with applications in tissue regeneration and in the development of pharmacological treatments designed to improve efficacy in the treatment of serious diseases such as breast cancer.

About ROVI

ROVI is an international pharmaceutical company specialising and engaging in the research, development, contract manufacturing and marketing of small molecules and biological specialties. The Company, in a continuous international expansion process, has subsidiaries in Portugal, Germany, the United Kingdom, Italy, France and Austria and maintains a diversified marketing portfolio of more than 40 products, among which its flagship product, bemiparin, also present in more than 60 countries all over the world, should be highlighted. Likewise, ROVI markets its enoxaparin biosimilar, developed in-house, in Europe and it is also present in approximately 60 countries. ROVI continues to drive the development the ISM® Platform technology, a leading-edge line of research in the field of prolonged drug release that has given rise to, among other innovations, Risperidone ISM® to treat schizophrenia in adults. For further information, please visit www.rovi.es.

For further enquiries, please contact:

Juan López-Belmonte Encina
Chairman and Chief Executive Officer
www.rovi.es

Javier López-Belmonte Encina
Deputy Chairman and Chief Financial Officer
www.rovi.es

Marta Campos Martínez
Head of Finance
+34 912444422
mcampos@rovi.es
www.rovi.es

Beatriz de Zavala Mazarredo
Investor Relations Analyst
+34 610 737 703
bdezavala@rovi.es
www.rovi.es

Victoria López-Belmonte
Investor Relations Analyst
+34 680 669 485
vlopez-belmonte@rovi.es
www.rovi.es

Forward-looking statements

This news release contains forward-looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance, or achievements of ROVI or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward looking statements. The statements in this press release represent ROVI's expectations and beliefs as of the date of this press release. ROVI anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while ROVI may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing ROVI's expectations or beliefs as of any date after the date of this press release.

APPENDIX 1

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2026 AND DECEMBER 31, 2025

IN € THOUSANDS*	June 30, 2026	December 31, 2025
ASSETS		
Non-current assets		
Property, plant and equipment	485,640	330,735
Goodwill	2,702	2,702
Intangible assets	32,992	33,183
Investments in joint ventures and associated companies	19,252	19,164
Deferred income tax asset	18,479	3,199
	559,065	**388,983**
Current assets		
Inventories	272,814	287,975
Trade and other receivables	162,433	177,540
Derivative financial instruments	—	29
Financial assets at amortised cost	1,103	—
Prepaid expenses	4,637	3,188
Cash and cash equivalents	126,969	97,976
	567,956	**566,708**
Total assets	**1,127,021**	**955,691**

**There has been a limited review of the figures for the first half of 2026 by the auditor. The figures as of December 31, 2025 are audited figures.*

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS AS OF JUNE 30, 2026 AND DECEMBER 31, 2025

IN € THOUSANDS*	June 30, 2026	December 31, 2025
EQUITY		
Equity attributed to parent company	**700,619**	**664,415**
Share capital	3,074	3,074
Share premium	87,636	87,636
Legal reserve	673	673
Treasury shares	(5,849)	(5,174)
Retained earnings and voluntary reserves	528,969	437,818
Profit for the period	84,476	140,442
Accumulated other comprehensive income	1,640	(54)
Non-controlling interests	**16,434**	**11,040**
Total equity	**717,053**	**675,455**
LIABILITIES		
Non-current liabilities		
Financial debt	80,544	93,204
Deferred income tax liabilities	21,768	160
Other non-current payables	195	191
Contract liabilities	27,816	2,016
Deferred income	3,100	3,443
	133,423	**99,014**
Current liabilities		
Financial debt	27,146	28,617
Trade and other payables	185,915	118,559
Current income tax liabilities	25,672	4,402
Contract liabilities	24,609	4,042
Deferred income	13,203	25,602
	276,545	**181,222**
Total liabilities	**409,968**	**280,236**
Total equity and liabilities	**1,127,021**	**955,691**

**There has been a limited review of the figures for the first half of 2026 by the auditor. The figures as of December 31, 2025 are audited figures.*

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED INCOME STATEMENTS FOR THE SIX-MONTH PERIODS ENDING JUNE 30, 2026 AND JUNE 30, 2025

IN € THOUSANDS*	H1 2026	H1 2025
Revenue	344,160	314,590
Changes in inventories of finished goods and work in progress	(15,116)	(1,373)
Raw materials and consumables used	(104,788)	(117,766)
Employee benefit expenses	(85,268)	(70,417)
Other operating expenses	(93,338)	(60,286)
Work carried out by the Group on non-current assets	258	232
Amortisation and depreciation	(17,973)	(14,748)
Recognition of government grants on non-financial non-current assets and other	12,846	715
Gain on bargain purchase	62,352	—
Share of profit in joint ventures and associated companies	88	(67)
OPERATING PROFIT (EBIT)	**103,221**	**50,880**
Finance income	877	707
Finance costs	(2,755)	(1,328)
Impairment and gain or loss on measurement of financial instruments	116	(533)
Exchange difference	112	(100)
FINANCE INCOME/(COSTS) - NET	**(1,650)**	**(1,254)**
PROFIT BEFORE INCOME TAX	**101,571**	**49,626**
Income tax	(17,192)	(9,926)
PROFIT FOR THE PERIOD	**84,379**	**39,700**
Profit for the year attributable to parent company	84,476	39,736
Profit attributable to non-controlling interests	(97)	(36)

**There has been a limited review of the figures for the first half of 2025 and the first half of 2026 by the auditor.*

LABORATORIOS FARMACÉUTICOS ROVI, S.A. AND SUBSIDIARIES
CONSOLIDATED CASH FLOW STATEMENTS FOR THE SIX-MONTH PERIODS ENDING JUNE 30, 2026 AND JUNE 30, 2025

IN € MILLIONS	H1 2026	H1 2025
Cash flows from operating activities		
Profit before income tax	101,571	49,626
Adjustments for non-monetary transactions:		
Amortisation and depreciation	17,973	14,748
Finance income	(877)	(707)
Loss allowance	398	(4,161)
Adjustments for changes in value of derivatives	(97)	61
Gain or loss on derecognitions of financial assets and liabilities	(19)	472
Finance expenses	2,755	1,328
Exchange rate differences	(112)	100
Gain on bargain purchase	(62,352)	—
Grants, distribution licenses and other deferred income	(13,086)	(973)
Gain or loss on disposal of fixed assets	1,766	—
Share in profit/(loss) of joint ventures and associated companies	(88)	67
Changes in working capital:		
Trade and other receivables	15,091	8,644
Inventories	16,449	6,310
Other current assets (prepaid expenses)	(969)	(1,962)
Trade and other payables	9,254	(25,565)
Other collections and payments:		
Cash flow from contract manufacturing services	10,123	(17,224)
Proceeds from distribution licenses	5	515
Proceeds from grants	—	3,764
Cash flow from taxes	(3,523)	(7,019)
Net cash generated from (used in) operating activities	**94,262**	**28,024**
Cash flows from investing activities		
Acquisitions of intangible assets	(1,545)	(679)
Acquisitions of property, plant and equipment (not including rights of use)	(28,878)	(20,159)
Proceeds from sale of property, plant and equipment	—	85
Other cash flows from investing activities	(23,258)	(3,222)
Other amounts received or paid	—	2,064
Net cash flows generated from (used in) investing activities	**(53,681)**	**(21,911)**
Cash flows from financing activities		
Repayments of financial debt	(14,488)	(32,574)
Proceeds from financial debt	—	46,521
Interest paid	(1,170)	(1,116)
Purchase of treasury shares	(39,265)	(28,380)
Reissue of treasury shares	38,808	28,364
Capital contribution in subsidiaries	4,388	—
Net cash flows generated from (used in) financing activities	**(11,727)**	**12,815**
Exchange rate differences	**139**	**—**
Net (decrease) increase in cash and cash equivalents	**28,993**	**18,928**
Cash & cash equivalents at beginning of the period	**97,976**	**27,186**
Cash and cash equivalents at end of the period	**126,969**	**46,114**

**There has been a limited review of the figures for the first half of 2025 and the first half of 2026 by the auditor.*

APPENDIX 2

ALTERNATIVE PERFORMANCE MEASURES

In addition to the financial information prepared in accordance with International Financial Reporting Standards ("IFRSs") taken from our financial statements, this document includes certain alternative performance measures ("APMs") as defined in the ESMA (European Securities and Markets Authority) Guidelines on Alternative Performance Measures of 5 October, 2015 (ESMA/2015/1415), as well as some non-IFRS financial indicators. The financial measures contained in this document that are considered APMs or non-IFRS financial indicators have been prepared on the basis of the ROVI Group's financial information but are not defined or set out in detail within the framework of the applicable financial information and have not been audited or reviewed by ROVI's auditors.

These APMs are considered figures that have been adjusted in respect of those that are presented in accordance with the International Financial Reporting Standards endorsed by the European Union (IFRS-EU), which form the applicable accounting framework for the consolidated financial statements of the ROVI Group. Therefore, the reader should consider them to complement the latter but not to replace them.

ROVI uses these APMs and non-IFRS financial indicators to plan, oversee and assess its performance. ROVI considers the APMs and non-IFRS financial indicators to be useful to allow the management team and investors to compare the past or future financial performance, the financial situation and the cash flows. Notwithstanding, these APMs and non-IFRS financial indicators are considered complementary and are not intended to replace IFRS measures. Furthermore, other companies, including some in ROVI's sector, may calculate such measures differently, which reduces their usefulness for comparative purposes.

This document contains information on the alternative performance measures (APMs) and non-IFRS financial indicators used by ROVI, including their definitions and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs. The document is available on ROVI's website and may be accessed on the following link: (https://www.rovi.es/en/shareholders-investors/financial-business-information).

In this respect, in accordance with the Guidelines issued by the European Securities and Markets Authority (ESMA), in force since 3 July, 2016, in relation to the transparency of Alternative Performance Measures, ROVI provides below information concerning the APMs it considers significant that are included in this press release:

- **Operating revenue**

This APM shows the revenue that the group generates from its main business activities.

Operating revenue refers to revenue.

- **Other revenue**

Other revenue shows the grants obtained by the Group to develop its R&D&I and other projects.

Other revenue refers to the recognition of government grants on non-financial non-current assets and other.

- **Total revenue**

This APM shows all the group's revenues.

We calculate total revenue as revenue plus the recognition of government grants on non-financial non-current assets and other.

- **Cost of sales**

The cost of sales reflects the cost involved in producing or acquiring the products or services that ROVI sells.

The cost of sales is calculated as the amount of raw materials and consumables used plus that corresponding to the changes in inventories of finished goods and work in progress.

- **Gross profit**

Gross profit is an indicator that measures the direct profit that ROVI obtains from carrying out its income-generating activities.

We calculate gross profit as total revenue less cost of sales.

- **Gross margin or gross profit as % of operating revenue**

This APM is a percentage indicator that measures the direct profit that ROVI obtains from its operating revenue.

We calculate gross margin or gross profit as % of operating revenue as the percentage that the gross profit represents in the revenue (operating revenue).

- **Research & Development ("R&D") Expenses**

R&D expenses reflect expenses related to scientific research and technological development carried out by ROVI.

R&D expenses are calculated as the sum of employee benefits expenses and other operating expenses related to scientific research and technological development.

- **SG&A Expenses**

Selling, General & Administrative (SG&A) Expenses is an indicator that measures expenses related to the general internal operations and management of the company.

SG&A calculated as the amount of employee benefit expenses plus other operating expenses plus work carried out by the Group on non-current assets" minus research & development expenses.

- **EBITDA**

EBITDA (Earnings Before Interest, Tax, Depreciation and Amortization) is an indicator that measures the group's operating profit before interest, taxes, impairment, depreciation and amortization have been deducted. Management uses it to assess the results over time, allowing a comparison with other companies in the sector.

We calculate EBITDA as profit before: taxes, interest, depreciation and amortization.

- **EBITDA margin or EBITDA as % of operating revenue**

This APM is a percentage indicator that measures the operating profit that ROVI obtains from its operating revenue before interest, taxes, impairment, depreciation and amortization are deducted.

We calculate EBITDA margin or EBITDA as % of operating revenue as the percentage that the EBITDA represents in the revenue (operating revenue).

- **EBITDA "Pre-R&D"**

This APM is used by ROVI to show EBITDA from the on-going business.

We calculate EBITDA "Pre-R&D" as EBITDA excluding: R&D expenses and non-recurring income and expenses.

- **EBIT**

EBIT (Earnings Before Interest and Taxes) is an indicator that measures the group's operating profit before interest and tax are deducted. Like EBITDA, Management uses it to assess the results over time, allowing a comparison with other companies in the sector.

We calculate EBIT as profit before: taxes and interest.

- **EBIT margin or EBIT as % of operating revenue**

This APM is a percentage indicator that measures the operating profit that ROVI obtains from its operating revenue before interest and tax are deducted.

We calculate EBIT margin or EBIT as % of operating revenue as the percentage that the EBIT represents in the revenue (operating revenue).

- **EBIT "Pre-R&D"**

This APM is used by ROVI to show EBIT from the on-going business.

We calculate EBIT "Pre-R&D" as operating profit for the period excluding: Research and Development expenses ("R&D") and non-recurring income and expenses.

- **Net profit**

Net profit is an indicator that measures the group´s profit for the period.

We calculate Net profit as EBIT plus finance costs-net and income tax.

- **Net profit as % of operating revenue**

This APM is a percentage indicator that measures the profit for the period that ROVI obtains from its operating revenue.

We calculate net profit as % of operating revenue as the percentage that the net profit represents in the revenue (operating revenue).

- **Net profit "Pre-R&D"**

This APM is used by ROVI to show the profit for the period related to the on-going business.

We calculate net profit "Pre-R&D" as EBIT "Pre-R&D" plus:

- Finance costs-net; and
- Income tax. Net profit "Pre-R&D" income tax is calculated by applying the same effective tax rate as reported in the income statement of the period.

- **Gross cash position**

Gross cash position is an indicator that measures the amount of cash the group has at a specific point in time.

We calculate gross cash position as equity securities plus deposits plus financial derivatives plus financial assets at amortised cost plus cash and cash equivalents.

- **Net debt (-)/cash (+)**

Net cash, also measured as financial debt or net debt, is the main indicator used by Management to measure the group's indebtedness.

It is composed of equity securities, plus deposits, plus financial derivatives, plus financial assets at amortised cost, plus cash and cash equivalents, less current and non-current financial debt.

- **Capex**

Capex is an indicator used to better understand the investments made by the group in its operations.

We calculate Capex as purchases of property, plant and equipment and intangible assets.

- **Capex as % of operating revenue**

This APM is a percentage indicator that measures the group's investments in property, plant and equipment, and intangible assets to its operating revenues.

We calculate Capex as % of operating revenue as the percentage that the purchases of property, plant and equipment and intangible assets represents in the revenue (operating revenue).

- **Free Cash Flow (FCF)**

Free cash flow is an indicator that measures cash flow generation from operating and investment activities and is useful for evaluating the funds available for paying shareholder dividends and servicing debt.

We calculate free cash flow as net cash generated from or used in operating activities less purchases of property, plant and equipment and intangible assets ("Capex") plus proceeds from sale of property, plant and equipment and intangible assets plus interest received.

- **FCF as % of operating revenue**

This APM is a percentage indicator that measures the group's cash flow generation from operating and investment activities relative to its operating revenues.

We calculate FCF as % of operating revenue as the percentage that the free cash flow represents in the revenue (operating revenue).